论文部分内容阅读
目的:观察口服中药健脾化痰汤治疗缓解期儿童哮喘的临床疗效。方法:将所有于医院儿科就诊的缓解期哮喘患儿共70例,随机分为治疗组与对照组两组,每组各35例。对照组:采用吸入布地奈德混悬液及口服孟鲁司特钠的方法治疗。治疗组:采用吸入布地奈德混悬液,同时口服自拟中药健脾化痰汤的方法治疗,两组疗程均为3个月,疗程结束后观察疗效。结果:研究结果显示,两组在临床总有效率比较中,治疗组总有效率为97.1%,对照组为74.3%,治疗组优于对照组,两组相比,差异显著,P<0.05。两组治疗前后症状积分疗效方面存在明显差异,治疗组优于对照组,P<0.05。两组治疗前后血清Ig E、IL-18、TNF-α水平比较,治疗组治疗后明显低于对照组,两组相比,存在显著差异,P<0.05。两组治疗后随访观察,治疗组在随访半年及1年时的平均发作次数均少于对照组,两组相比,有统计学差异,P<0.05。结论:采用中药健脾化痰汤口服对改善哮喘患儿临床症状及减少复发次数具有明显效果,且该疗法费用低廉,安全性高,且无明显不良反应,值得临床推广应用。
Objective: To observe the clinical effect of oral administration of Jianpi Huatan Decoction on children with asthma during remission. Methods: A total of 70 children with asthma undergoing remission in pediatric hospital were randomly divided into treatment group and control group with 35 cases in each group. Control group: inhaled budesonide suspension and oral montelukast sodium treatment. Treatment group: inhaled budesonide suspension, oral self-made method of spleen and phlegm soup treatment, the two groups were 3 months course of treatment, after the end of treatment observed the effect. Results: The results showed that the total effective rate in the two groups was 97.1% in the treatment group and 74.3% in the control group. The treatment group was superior to the control group, and the difference was significant (P <0.05). There were significant differences between the two groups in symptom score before and after treatment, the treatment group was superior to the control group, P <0.05. The levels of serum IgE, IL-18 and TNF-α in the two groups before and after treatment were significantly lower than those in the control group after treatment, with significant difference between the two groups (P <0.05). Follow-up observation after treatment in both groups showed that the mean number of attacks in the treatment group at 6 months and 1 year of follow-up was less than that in the control group. There was significant difference between the two groups (P <0.05). Conclusion: The Chinese medicine spleen phlegm decoction oral administration can improve the clinical symptoms and reduce the number of relapse in children with asthma. The therapy has the advantages of low cost, high safety and no obvious adverse reactions. It is worthy of clinical application.